

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Michael S. Kinch et al.

Serial No.: 09/640,952

Filed: 17 August 2000

Confirmation No.: 3252



Group Art Unit: 1642

Examiner: Natalie A. Davis

Docket No.: 290.0009 0101

TECH CENTER 1600/2900

JUN 06 2002

RECEIVED

Title: EPHA2 AS A DIAGNOSTIC TARGET FOR METASTATIC CANCER (As Amended)

Assistant Commissioner for Patents
Washington, D.C. 20231

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

- ☒ An itemized return postcard.
- ☒ A Petition for Extension of Time for 2 month(s) and a check in the amount of \$400 for the required fee.
- ☒ A Supplemental Information Disclosure Statement (3 pgs); copies of 0 applications; 1449 forms (2 pgs); and copies of 13 documents cited on the 1449 forms and a copy of *In re John Kollar*.
- ☒ A check in the amount of \$180, for Supplemental Information Disclosure Statement.
- ☐ A certified copy of a application, Serial No. , filed , the right of priority of which is claimed under 35 U.S.C. §119.
- ☒ Other: Statement of Availability (2 pgs), Declaration Under 37 C.F.R. §1.132 (2 pgs.) and copies of 4 license agreements.
- ☒ Amendment and Response (18 pgs. total including Appendix A (10 pgs.))
- ☒ X No Additional fee is required. The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$18 =	
Independent Claims				x \$84 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$280 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

MUETING, RAASCH & GEBHARDT, P.A.

Customer Number: 26813



26813

PATENT TRADEMARK OFFICE

By: Victoria A. Sandberg
Name: Victoria A. Sandberg
Reg. No.: 41,287
Direct Dial: 612-305-1226
Facsimile: 612-305-1228

CERTIFICATE UNDER 37 CFR §1.10:

"Express Mail" mailing label number: EV073730822US

Date of Deposit: 30 May 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By: Jacquelyn K. Torborg
Name: JACQUELYN K. TORBORG

(LARGE ENTITY TRANSMITTAL UNDER RULE 1.10)

1A



RECEIVED
JUN 19 2002
TECH CENTER 1600/2900
PATENT

Docket No. 290.0009010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Michael S. Kinch et al.) Group Art Unit: 1642
Serial No.: 09/640,952)
Confirmation No.: 3252)
Filed: 17 August 2000)
For: EPHA2 AS A DIAGNOSTIC TARGET FOR METASTATIC CANCER (As Amended)

STATEMENT OF AVAILABILITY

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

1. I am an attorney of record in the above-entitled application.
2. Hybridoma cell lines D7 and B2D6, referred to at page 4, lines 6-12, were deposited and are available from the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA, 20110-2209, USA, on December 8, 2000, in accordance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, as evidenced by the attached copies of the Deposit Receipts.
3. Hybridoma cell line D7 was identified as "murine hybridoma D7" and was assigned ATCC number PTA 2755.
4. Hybridoma cell line B2D6 was identified as "murine hybridoma B2D6," was assigned ATCC number PTA 2754.

RECEIVED

JUN 06 2002

TECH CENTER 1600/2900

Page 2 of 2



Statement of Availability

Serial No.: 09/640,952

Confirmation No.: 3252

Filed: 17 August 2000

For: EPHA2 AS A DIAGNOSTIC TARGET FOR METASTATIC CANCER (As Amended)

5. Upon issuance of a patent out of the above-identified application, all restrictions, subject to the provisions of 37 C.F.R. 1.808(b), upon the availability of hybridoma cell lines D7 and B2D6 to the public will be irrevocably removed, and the deposits will be replaced if viable samples cannot be dispensed by the depository.

CERTIFICATE UNDER 37 C.F.R. 1.10:

The undersigned hereby certifies that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Jacquelyn K. Tuerberg
JACQUELYN K. TUEBERG

"Express Mail" mailing label number:

EV073730822US

Date of Deposit: 30 May 2002

Respectfully submitted for

Purdue Research Foundation

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220

Facsimile: (612)305-1228

Customer Number 26813



26813

PATENT TRADEMARK OFFICE

May 30, 2002
Date

By: *Victoria A. Sandberg*
Victoria A. Sandberg
Reg. No. 41,287
Direct Dial (612)305-1226